Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $251.00 price target on the stock.
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Natera, Inc. (NASDAQ: NTRA) had its "buy" rating re-affirmed by analysts at BTIG Research.
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer [Yahoo! Finance]
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer